

## Pseudolymphoma of the liver associated with primary biliary cirrhosis: A case report and review of literature

Toshihide Okada, Hiroshi Mibayashi, Kenkei Hasatani, Yoshiaki Hayashi, Shigetsugu Tsuji, Yoshibumi Kaneko, Masashi Yoshimitsu, Takashi Tani, Yoh Zen, Masakazu Yamagishi

Toshihide Okada, Hiroshi Mibayashi, Kenkei Hasatani, Yoshiaki Hayashi, Shigetsugu Tsuji, Yoshibumi Kaneko, Masashi Yoshimitsu, Masakazu Yamagishi, Department of Internal Medicine, Kanazawa University Graduate School of Medical Science, 13-1, Takaramachi, Kanazawa 920-8641, Japan  
Takashi Tani, Department of Gastroenterologic Surgery, Kanazawa University Hospital, 13-1, Takaramachi, Kanazawa 920-8641, Japan

Yoh Zen, Department of Human Pathology, Kanazawa University Hospital, Kanazawa 920-8641, Japan

**Author contributions:** Okada T and Mibayashi H contributed equally to this work; Hasatani K, Hayashi Y, Tsuji S, Kaneko Y and Yoshimitsu M performed clinical examinations; Tani T was in charge of surgery; Zen Y was in charge of pathological diagnosis; Okada T, Mibayashi H and Yamagishi M wrote the paper.

**Correspondence to:** Toshihide Okada, MD, Department of Internal Medicine, Kanazawa University Graduate School of Medical Science, 13-1, Takaramachi, Kanazawa 920-8641, Japan. [okada351116@yahoo.co.jp](mailto:okada351116@yahoo.co.jp)

Telephone: +81-76-2652000 Fax: +81-76-2344251

Received: April 10, 2009 Revised: August 14, 2009

Accepted: August 21, 2009

Published online: September 28, 2009

pseudolymphoma into lymphoma in the liver, the exact nature of development from benign pseudolymphoma to malignant lymphoma is still not fully understood and cases of hepatic lymphoma need to be followed carefully.

© 2009 The WJG Press and Baishideng. All rights reserved.

**Key words:** Liver diseases; Pseudolymphoma; Primary biliary cirrhosis

**Peer reviewer:** Hong-Xiang Liu, PhD, Department of Pathology, Division of Molecular Histopathology, University of Cambridge, Box 231, Level 3, Lab Block, Addenbrooke's Hospital, Hills Road, Cambridge CB2 2QQ, United Kingdom

Okada T, Mibayashi H, Hasatani K, Hayashi Y, Tsuji S, Kaneko Y, Yoshimitsu M, Tani T, Zen Y, Yamagishi M. Pseudolymphoma of the liver associated with primary biliary cirrhosis: A case report and review of literature. *World J Gastroenterol* 2009; 15(36): 4587-4592  
Available from: URL: <http://www.wjgnet.com/1007-9327/15/4587.asp> DOI: <http://dx.doi.org/10.3748/wjg.15.4587>

### Abstract

We report a case of two pseudolymphomas of the liver in a 63-year-old Japanese woman with primary biliary cirrhosis. One of the lesions was found incidentally during a medical examination, presenting as a 10 mm hypodense nodule that revealed hyperdensity in the early phase and hypodensity in the late phase in computed tomography (CT) after injection of contrast medium. Retrospectively, the 10 mm nodule had first been discovered as a 4 mm nodule during CT 4 years previously. Superparamagnetic iron oxide-enhanced MRI revealed another 4 mm hyperintense nodule in segment 6 in addition to the 10 mm hyperintense nodule in segment 7. CT during arterial portography revealed two hypointense nodules. Findings with other imaging modalities such as ultrasonography, magnetic resonance imaging, and hepatic angiography were consistent with hepatocellular carcinoma. A right posterior segmentectomy was performed, and the lesions were microscopically diagnosed as pseudolymphoma. To the best of our knowledge, only 31 other cases of this disease have ever been reported, with a highly asymmetrical male:female ratio of 1:9.7. Although we could find only one case of transformation of hepatic


### INTRODUCTION

Pseudolymphoma in the liver is an extremely rare disease. Although the exact etiology remains unknown, it is speculated that the disorder is a reactive immunological response to a chronic infection or inflammation<sup>[1]</sup>; hepatic pseudolymphoma can develop in patients with autoimmune diseases<sup>[2,3]</sup>, malignancy<sup>[4]</sup>, or hepatitis<sup>[5]</sup> or who are administered interferon therapy<sup>[6]</sup>. It has been reported that diagnosis of pseudolymphoma is difficult without histopathological examination, since image findings are quite similar to hepatocellular carcinoma (HCC)<sup>[2]</sup>. Although pseudolymphoma is generally thought to be benign, the risk of malignant transformation into lymphoma remains controversial.


We report a case of hepatic pseudolymphoma in a female Japanese patient with primary biliary cirrhosis (PBC) and discuss the literature.

### CASE REPORT

A 63-year-old female with a history of PBC and resection of the left adrenal gland for primary aldosteronism, was admitted to our hospital for further evaluation of




**Figure 1** Computed tomography (CT) showing a 10 mm nodule in segment 7. A: A hypodense nodule in plane phase; B: A hyperdense nodule in the early phase after injection of contrast medium; C: A hypodense nodule in the late phase after injection of contrast medium.




**Figure 2** Magnetic resonance imaging (MRI) showing a 10 mm nodule in segment 7. A: A hypointense nodule on T1-weighted images; B: A hyperintense nodule on T2-weighted images; C: A hyperintense nodule in the early phase after injection of contrast medium; D: A hypointense nodule in the late phase after injection of contrast medium.

a hepatic lesion incidentally discovered in abdominal computed tomography (CT). The patient had taken only ursodeoxycholic acid 300 mg/d for PBC for 10 years and had not taken immunosuppressive agents. The patient was asymptomatic on admission and her condition was generally good. She had a surgical scar on her abdomen. We noted no hepatosplenomegaly, lymphadenopathy, or peripheral edema. Laboratory tests showed a prothrombin time of 11.8 s (normal, 10.8-13.3), a total bilirubin level of 0.6 mg/dL (normal, 0.3-1.2), and an albumin level of 4.0 g/dL (normal, 4.0-5.0). Her serum alkaline phosphatase level was 350 IU/L (normal, 115-359),  $\gamma$ -glutamyltransferase 48 IU/L (normal, 10-47), aspartate aminotransferase 24 IU/L (normal, 13-33), and alanine aminotransferase 16 IU/L (normal, 6-27). Serology examinations for hepatitis B and C viruses were negative. Rheumatoid factor antibodies, Sjögren syndrome-A antibodies, and Sjögren syndrome-B antibodies were negative. Antinuclear antibodies and antimitochondrial


antibodies were positive. Immunoglobulin G, immunoglobulin M, and immunoglobulin A were within normal ranges. Alpha-fetoprotein, protein induced by vitamin K absence, and carcinoembryonic antigen were within normal ranges. A urea breath test was negative. Abdominal ultrasonography showed a hypoechoic lesion, 10 mm in diameter in segment 7 (data not shown). CT demonstrated a 10 mm hypodense nodule that revealed hyperdensity in the early phase and hypodensity in the late phase after injection of contrast medium (Figure 1). Retrospectively, this nodule had previously shown up as a 4 mm nodule in a CT performed for examination of an adrenal tumor 4 years previously (data not shown). Magnetic resonance imaging (MRI) showed a hypointense nodule on T1-weighted images and a hyperintense nodule on T2-weighted images in segment 7. Following injection of contrast MRI, a hyperintense nodule in the arterial phase and a hypointense nodule in the portal phase were revealed (Figure 2). Superparamagnetic iron oxide-



**Figure 3** Superparamagnetic iron oxide-enhanced MRI showing hyperintense nodules. A: 10 mm nodule in segment 7; B: 4 mm nodule in segment 6.



**Figure 4** CT during arterial portography showing hypointense nodules. A: 10 mm nodule in segment 7; B: 4 mm nodule in segment 6.



**Figure 5** The pathological findings of the lesions. A: Macroscopically, the lesion was white and hard with a clear margin (a lesion in segment 7); B: Microscopically, the lesion consisted of a nodular lymphoid infiltrate with germinal centers (a lesion in segment 7), HE stain ( $\times 40$ ); Lymphocytes in the lesions consisted of CD3-positive T-cells (C) and CD20-positive B-cells (D), Both  $\times 100$ ; E: Stained for  $\kappa$  light chains with *in situ* hybridization ( $\times 200$ ); F: Stained for  $\lambda$  light chains with *in situ* hybridization ( $\times 200$ ).

enhanced MRI revealed another 4 mm hyperintense nodule in segment 6 in addition to the 10 mm hyperintense nodule in segment 7 (Figure 3). Although angiography *via* the common hepatic artery did not demonstrate tumor staining, CT during arterial portography revealed two hypointense nodules (Figure 4). Imaging findings suggested HCC, although no other hypervascular tumor could be excluded. The patient received an explanation of the results, including the possibility of a benign tumor, and expressed a desire for surgical extraction of the nodules. A right posterior segmentectomy was

performed. Macroscopically, the lesion in segment 7 was white and hard with clear margins (Figure 5A) and the lesion in segment 6 was not detected. Microscopically, two lesions showed similar histological features. The lesions exhibited a nodular infiltration of mature small lymphoid cells with many lymph follicles. No obvious atypical cells were identified in both lesions. Bile ducts were identified at the periphery of the lesions, although characteristic lymphoepithelial lesions could not be identified. No necrosis or granulomatous inflammation was identified (Figure 5B). Pseudolymphoma and extranodal marginal



Table 1 Reported cases of hepatic pseudolymphoma

No.	Author (reference)	Age	Sex	No.	Size (cm)	Pathological diagnosis	Association
1	Snover <i>et al</i> <sup>[32]</sup>	15	F	1		PL	Combined immunodeficiency, liver fibrosis
2	Grouls <i>et al</i> <sup>[1]</sup>	85	F	2	1.4, 0.8	PL	Gastric cancer
3	Tanabe <i>et al</i> <sup>[33]</sup>	30	F	1	1.5	PL	Acute enteritis
4	Isobe <i>et al</i> <sup>[34]</sup>	59	F	1	0.9	RLH	Diabetes mellitus
5	Ohtsu <i>et al</i> <sup>[6]</sup>	42	F	1	1.5	PL	Chronic hepatitis B, interferon- $\alpha$ therapy
6	Katayanagi <i>et al</i> <sup>[35]</sup>	66	F	2	1.5, 1.0	PL	Diabetes mellitus
7	Tanizawa <i>et al</i> <sup>[36]</sup>	67	F	1	2	RLH	Abnormal liver function
8	Endo <i>et al</i> <sup>[37]</sup>	38	F	1	1.8	PL	Pancytopenia
9	Kim <i>et al</i> <sup>[5]</sup>	72	M	1	1.7	PL	Chronic hepatitis C, gastric cancer
10	Fujinaga <i>et al</i> <sup>[38]</sup>	58	F	1	1.5	PL	Hypertension
11	Nishijima <i>et al</i> <sup>[39]</sup>	58	F	1	1.2	PL	Hypertension, diabetes mellitus
12	Sharifi <i>et al</i> <sup>[3]</sup>	52	F	1	0.4	NLL	Primary biliary cirrhosis
13		56	F	1	1.5	NLL	Primary biliary cirrhosis, CREST syndrome
14		56	M	1	0.7	NLL	Diverticulitis
15	Nagano <i>et al</i> <sup>[40]</sup>	47	F	1	1.7	RLH	Chronic thyroiditis, high titer of ANA
16	Pantanowitz <i>et al</i> <sup>[41]</sup>	69	F	2	1.7, 1.0	RLH	Renal cell carcinoma
17	Okubo <i>et al</i> <sup>[2]</sup>	49	F	1	2	PL	Sjögren's syndrome
18	Mori <i>et al</i> <sup>[42]</sup>	49	F	1	1.8	PL	Chronic hepatitis B
19	Okuhama <i>et al</i> <sup>[43]</sup>	70	M	1	4	PL	
20	Shiozawa <i>et al</i> <sup>[44]</sup>	51	F	1	2	PL	
21	Takahashi <i>et al</i> <sup>[45]</sup>	77	F	1	1.5	RLH	Colon cancer
22		64	F	2	0.9, 0.7	RLH	Colon cancer
23	Maehara <i>et al</i> <sup>[46]</sup>	72	F	2	1.3, 1.0	RLH	
24	Willenbrock <i>et al</i> <sup>[47]</sup>	36	F	1	1.8	NLL	Ovarian cyst, focal nodular hyperplasia of the liver
25	Sato <i>et al</i> <sup>[4]</sup>	75	F	1	1.4	RLH	Gastric cancer, colon cancers, metastatic liver tumor
27	Ota <i>et al</i> <sup>[20]</sup>	63	F	1	1.6	PL	Gastric ulcer, <i>Helicobacter pylori</i> infection
28	Machida <i>et al</i> <sup>[48]</sup>	53	F	3	1.5, 1.2, 1.0	RLH	Autoimmune thyroiditis
29	Matsumoto <i>et al</i> <sup>[49]</sup>	67	F	1	1.5	PL	Hypertension
30	Jiménez <i>et al</i> <sup>[50]</sup>	34	F	1	2.3	NLH	Hypothyroidism
31	Park <i>et al</i> <sup>[51]</sup>	46	F	2	1.0, 1.0	RLH	Renal cell carcinoma
32	Present case	63	F	2	1.3, 0.4	PL	Primary biliary cirrhosis, primary aldosteronism

RLH: Reactive lymphoid hyperplasia; PL: Pseudolymphoma; NLL: Nodular lymphoid lesion; NLH: Nodular lymphoid hyperplasia; CREST: Calcinosis, Raynaud's phenomenon, esophageal dysmotility, sclerodactyly, telangiectasia; ANA: Antinuclear antibody.

zone B-cell lymphoma (MALToma) were differential diagnosis. Then, we performed immunohistochemical analysis and *in situ* hybridization. Immunostainings for CD3, CD20, and CD79 revealed regularly distributed T cells and B cells (Figure 5C and D). Plasma cells were not many in number in the lesions, but *in situ* hybridization for immunoglobulin light chains was performed because it is one of the useful tools to discriminate between reactive lymphoid lesions and MALToma. *In situ* hybridization revealed no significant difference between the numbers of cells positive for kappa-chain and lambda-chain (Figure 5E and F). Based on these histological features, the lesions were diagnosed as pseudolymphoma.

In the background liver, liver parenchyma showed bridging fibrosis with lymphoid infiltrate in portal tracts. Granulomas cholangitis and ductopenia were identified. Those histological features were consistent with Stage 2 PBC. The patient had an uneventful postoperative course and has shown no sign of recurrence for 11 mo.

## DISCUSSION

In the liver, pseudolymphoma has also been variously termed as reactive lymphoid hyperplasia and nodular lymphoid lesion, and shows histological features of hyperplastic lymphoid follicles with polymorphic and polyclonal cell populations composed of small mature

lymphocytes, mature plasma cells, macrophages, stroma fibrosis and often numerous germinal centers. It is usually localized and well demarcated from surrounding tissue<sup>[1]</sup>. Pseudolymphoma may occur at numerous sites including the stomach<sup>[7]</sup>, lung<sup>[8]</sup>, ocular adnexa<sup>[9]</sup>, hard palate and oral mucosa<sup>[10]</sup>, skin<sup>[11]</sup>, and breast<sup>[12]</sup>.

To the best of our knowledge, 32 cases (including ours) of hepatic pseudolymphoma have been reported in the English and Japanese literature (Table 1). There was a strongly asymmetric male-to-female ratio of 1:9.7 (3 M/29 F). While other sites of pseudolymphoma also tended to show asymmetry, only pseudolymphoma of the breast approached that of the liver in terms of asymmetry magnitude. All seven reported cases of breast pseudolymphoma were female<sup>[12]</sup>, but breast examination is limited almost exclusively to females, which could bias these findings. Reported male-female ratios of pseudolymphoma of the hard palate and oral mucosa<sup>[10]</sup>, lung<sup>[8]</sup>, and skin<sup>[11]</sup> were 1:2.8, 1:1.2 and 1:1.8, respectively, while ocular adnexal lymphoid hyperplasia affects men and women about equally<sup>[9]</sup>. Thus the extreme female asymmetry of hepatic pseudolymphoma is a unique characteristic.

Eight of 32 cases of hepatic lymphoma were associated with autoimmune disease and eight with malignant tumor (Table 1). In the lung, cases of pseudolymphoma associated with autoimmune disorders

such as Sjögren's disease were reported<sup>[13]</sup>, which is similar to the liver. In other organs, several factors are thought to be associated with pseudolymphoma, i.e. Epstein-Barr virus (hard palate and oral mucosa<sup>[14]</sup>), mechanical stimulation (ear<sup>[15]</sup>), anticonvulsant drugs (skin<sup>[16]</sup>) and *Helicobacter pylori* (*H. pylori*) (stomach<sup>[17,18]</sup>). Regarding the association of *H. pylori* with gastric pseudolymphoma, successful treatment of the pseudolymphoma by eradication of *H. pylori* has been reported<sup>[19]</sup>. Ota *et al.*<sup>[20]</sup> reported a case of hepatic pseudolymphoma in which the diameter decreased after *H. pylori* eradication. In the case reported here, the patient had no *H. pylori* infection.

Transformation of pseudolymphoma to lymphoma has been discussed. Malignant transformation of pseudolymphomas in the lung<sup>[21]</sup> and stomach<sup>[22]</sup> have been reported. These reports, however, either predated or did not include the use of immunofluorescent techniques. It is likely that these cases were in fact the early stage of primary lymphoma misinterpreted as benign<sup>[8]</sup>. On the other hand, evidence of progression from histologically benign, immunohistochemically polyclonal lymphoid infiltrates to malignant lymphoma in cutaneous pseudolymphoma is well delineated in the literature<sup>[23]</sup>. A potential association between lymphoma and PBC is suggested on the basis of individual reports in the literature<sup>[24-29]</sup>. In a retrospective study by Panjala *et al.*<sup>[30]</sup> based on an estimated 2,912 patients evaluated at their institution during a 22-year period, only 13 (an estimated 0.6%) patients were evaluated in referral visits for evidence of lymphoma. Although we could find one case of transformation of hepatic pseudolymphoma into lymphoma<sup>[31]</sup>, we were unable to deduce the long term natural course of hepatic pseudolymphoma since most reported cases of hepatic lymphoma underwent surgical resection.

In conclusion, we have reported a case of hepatic pseudolymphoma associated with PBC. Hepatic pseudolymphoma appears unique in its female preponderance and associated diseases. If hypervascular nodules in the liver of female patients with autoimmune disease are found, the possibility of pseudolymphoma should be considered. Cases of hepatic pseudolymphoma should be followed carefully as the exact nature of this disorder is still not fully understood.

## REFERENCES

- 1 Grouls V. Pseudolymphoma (inflammatory pseudotumor) of the liver. *Zentralbl Allg Pathol* 1987; **133**: 565-568
- 2 Okubo H, Maekawa H, Ogawa K, Wada R, Sekigawa I, Iida N, Maekawa T, Hashimoto H, Sato N. Pseudolymphoma of the liver associated with Sjogren's syndrome. *Scand J Rheumatol* 2001; **30**: 117-119
- 3 Sharifi S, Murphy M, Loda M, Pinkus GS, Khettry U. Nodular lymphoid lesion of the liver: an immune-mediated disorder mimicking low-grade malignant lymphoma. *Am J Surg Pathol* 1999; **23**: 302-308
- 4 Sato K, Ueda Y, Yokoi M, Hayashi K, Kosaka T, Katsuda S. Reactive lymphoid hyperplasia of the liver in a patient with multiple carcinomas: a case report and brief review. *J Clin Pathol* 2006; **59**: 990-992
- 5 Kim SR, Hayashi Y, Kang KB, Soe CG, Kim JH, Yang MK, Itoh H. A case of pseudolymphoma of the liver with chronic hepatitis C. *J Hepatol* 1997; **26**: 209-214
- 6 Ohtsu T, Sasaki Y, Tanizaki H, Kawano N, Ryu M, Satake M, Hasebe T, Mukai K, Fujikura M, Tamai M. Development of pseudolymphoma of liver following interferon-alpha therapy for chronic hepatitis B. *Intern Med* 1994; **33**: 18-22
- 7 Tokunaga O, Watanabe T, Morimatsu M. Pseudolymphoma of the stomach. A clinicopathologic study of 15 cases. *Cancer* 1987; **59**: 1320-1327
- 8 Holland EA, Ghahremani GG, Fry WA, Victor TA. Evolution of pulmonary pseudolymphomas: clinical and radiologic manifestations. *J Thorac Imaging* 1991; **6**: 74-80
- 9 Knowles DM, Jakobiec FA, McNally L, Burke JS. Lymphoid hyperplasia and malignant lymphoma occurring in the ocular adnexa (orbit, conjunctiva, and eyelids): a prospective multiparametric analysis of 108 cases during 1977 to 1987. *Hum Pathol* 1990; **21**: 959-973
- 10 Menasce LP, Shanks JH, Banerjee SS, Harris M. Follicular lymphoid hyperplasia of the hard palate and oral mucosa: report of three cases and a review of the literature. *Histopathology* 2001; **39**: 353-358
- 11 Baldassano MF, Bailey EM, Ferry JA, Harris NL, Duncan LM. Cutaneous lymphoid hyperplasia and cutaneous marginal zone lymphoma: comparison of morphologic and immunophenotypic features. *Am J Surg Pathol* 1999; **23**: 88-96
- 12 Maldonado ME, Sierra RD. Pseudolymphoma of the breast: case report and literature review. *Mil Med* 1994; **159**: 469-471
- 13 Song MK, Seol YM, Park YE, Kim YS, Lee MK, Lee CH, Jeong YJ. Pulmonary nodular lymphoid hyperplasia associated with Sjogren's syndrome. *Korean J Intern Med* 2007; **22**: 192-196
- 14 Samoszuk M, Ramzi E, Ravel J. Disseminated persistent lymphoid hyperplasia containing Epstein-Barr virus and clonal rearrangements of DNA. *Diagn Mol Pathol* 1993; **2**: 57-60
- 15 Zilinsky I, Tsur H, Trau H, Orenstein A. Pseudolymphoma of the earlobes due to ear piercing. *J Dermatol Surg Oncol* 1989; **15**: 666-668
- 16 Harris DW, Ostlere L, Buckley C, Whittaker S, Sweny P, Rustin MH. Phenytoin-induced pseudolymphoma. A report of a case and review of the literature. *Br J Dermatol* 1992; **127**: 403-406
- 17 Lee EY, Brady L, Yousefzadeh DK, Benya EC. Lymphoid hyperplasia of the stomach caused by *Helicobacter pylori*: upper gastrointestinal findings. *AJR Am J Roentgenol* 1999; **173**: 362-363
- 18 Chen XY, Liu WZ, Shi Y, Zhang DZ, Xiao SD, Tytgat GN. *Helicobacter pylori* associated gastric diseases and lymphoid tissue hyperplasia in gastric antral mucosa. *J Clin Pathol* 2002; **55**: 133-137
- 19 Weston AP, Campbell DR, McGregor DH, Cherian R. Endoscopic and histologic resolution of gastric pseudolymphoma (reactive lymphoid hyperplasia) following treatment with bismuth and oral antibiotics. *Dig Dis Sci* 1994; **39**: 2567-2574
- 20 Ota H, Isoda N, Sunada F, Kita H, Higashisawa T, Ono K, Sato S, Ido K, Sugano K. A case of hepatic pseudolymphoma observed without surgical intervention. *Hepatol Res* 2006; **35**: 296-301
- 21 Koss MN, Hochholzer L, Nichols PW, Wehunt WD, Lazarus AA. Primary non-Hodgkin's lymphoma and pseudolymphoma of lung: a study of 161 patients. *Hum Pathol* 1983; **14**: 1024-1038
- 22 Brooks JJ, Enterline HT. Gastric pseudolymphoma. Its three subtypes and relation to lymphoma. *Cancer* 1983; **51**: 476-486
- 23 Kulow BF, Cualing H, Steele P, VanHorn J, Breneman JC, Mutasim DF, Breneman DL. Progression of cutaneous B-cell pseudolymphoma to cutaneous B-cell lymphoma. *J Cutan Med Surg* 2002; **6**: 519-528
- 24 Prabhu RM, Medeiros LJ, Kumar D, Drachenberg CI, Papadimitriou JC, Appelman HD, Johnson LB, Laurin J, Heyman M, Abruzzo LV. Primary hepatic low-grade B-cell

- lymphoma of mucosa-associated lymphoid tissue (MALT) associated with primary biliary cirrhosis. *Mod Pathol* 1998; **11**: 404-410
- 25 **Ye MQ**, Suriawinata A, Black C, Min AD, Strauchen J, Thung SN. Primary hepatic marginal zone B-cell lymphoma of mucosa-associated lymphoid tissue type in a patient with primary biliary cirrhosis. *Arch Pathol Lab Med* 2000; **124**: 604-608
  - 26 **Ijichi S**, Iwata S, Une F, Tara M, Igata A. [B cell malignancy associated with Sjogren syndrome and primary biliary cirrhosis: a case report and review] *Rinsho Ketsueki* 1987; **28**: 911-916
  - 27 **de Figueiredo M**, Lima M, Macedo G, Ribeiro P. Association of splenic lymphoma with villous lymphocytes and primary biliary cirrhosis in a man. *Sangre (Barc)* 1996; **41**: 262-263
  - 28 **Goldin R**, Sayer J, Wilkins M, Price P, Thomas H. Primary liver lymphoma associated with primary biliary cirrhosis. *Histopathology* 1993; **22**: 184-185
  - 29 **Lizarralde E**, Martinez P, Ibanez T, Gutierrez A. Primary hepatic lymphoma and primary biliary cirrhosis. *Am J Gastroenterol* 2000; **95**: 562-563
  - 30 **Panjala C**, Talwalkar JA, Lindor KD. Risk of lymphoma in primary biliary cirrhosis. *Clin Gastroenterol Hepatol* 2007; **5**: 761-764
  - 31 **Sato S**, Masuda T, Oikawa H, Satoh T, Suzuki Y, Takikawa Y, Yamazaki K, Suzuki K, Sato S. Primary hepatic lymphoma associated with primary biliary cirrhosis. *Am J Gastroenterol* 1999; **94**: 1669-1673
  - 32 **Snover DC**, Filipovich AH, Dehner LP, Krivit W. 'Pseudolymphoma'. A case associated with primary immunodeficiency disease and polyglandular failure syndrome. *Arch Pathol Lab Med* 1981; **105**: 46-49
  - 33 **Tanabe Y**, Yano K, Yoshida Y, Sato T, Sakai K, Koyanagi N. A resectable case of pseudolymphoma of the liver (in Japanese). *Jpa J Gastroenterol* 1991; **16**: 240
  - 34 **Isobe H**, Sakamoto S, Sakai H, Masumoto A, Sonoda T, Adachi E, Nawata H. Reactive lymphoid hyperplasia of the liver. *J Clin Gastroenterol* 1993; **16**: 240-244
  - 35 **Katayanagi K**, Terada T, Nakanuma Y, Ueno T. A case of pseudolymphoma of the liver. *Pathol Int* 1994; **44**: 704-711
  - 36 **Tanizawa T**, Eishi Y, Kamiyama R, Nakahara M, Abo Y, Sumita T, Kawano N. Reactive lymphoid hyperplasia of the liver characterized by an angiofollicular pattern mimicking Castleman's disease. *Pathol Int* 1996; **46**: 782-786
  - 37 **Nishijima K**, Shimizu Y, Oonishi K, Hasebe K, Tani S, Hashimoto T, Yagi M, Miwa K, Nonomura A. A case of pseudolymphoma of the liver (in Japanese). *Acta Hepatol Jpa* 1998; **39**: 23-27
  - 38 **Fujinaga Y**, Matsui O, Shimizu K. Reactive lymphoid hyperplasia of the liver (in Japanese). *Jpn J Diagn Imaging* 1997; **17**: 586
  - 39 **Nichijima K**, Shimizu Y, Oonishi K, Hasebe K, Tani S, Hashimoto T. A case of pseudolymphoma of the liver (in Japanese). *Acta Hepatol Jpa* 1998; **39**: 23-27
  - 40 **Nagano K**, Fukuda Y, Nakano I, Katano Y, Toyoda H, Nonami T, Nagasaka T, Hayakawa T. Reactive lymphoid hyperplasia of liver coexisting with chronic thyroiditis: radiographical characteristics of the disorder. *J Gastroenterol Hepatol* 1999; **14**: 163-167
  - 41 **Pantanowitz L**, Saldinger PF, Kadin ME. Pathologic quiz case: Hepatic mass in a patient with renal cell carcinoma. *Arch Pathol Lab Med* 2001; **125**: 577-578
  - 42 **Mori M**, Koga Y, Dairaku K, Kishikawa M. A case of pseudolymphoma of the liver (in Japanese). *Acta Hepatol Jpa* 2002; **43**: 376-380
  - 43 **Okuhama Y**, Kenjyo T, Oomine M, Kaneshiro T, Shikiya M. A case of pseudolymphoma of the liver (in Japanese). *Shoukakigeka* 2003; **26**: 1557-1562
  - 44 **Shiozawa K**, Kinoshita H, Tsuruta H, Nakamura K, Naito S, Koga M, Takeshima F, Omagari K, Mizuta Y, Murata I, Kohno S. [A case of pseudolymphoma of the liver diagnosed before operation] *Nippon Shokakibyo Gakkai Zasshi* 2004; **101**: 772-778
  - 45 **Takahashi H**, Sawai H, Matsuo Y, Funahashi H, Satoh M, Okada Y, Inagaki H, Takeyama H, Manabe T. Reactive lymphoid hyperplasia of the liver in a patient with colon cancer: report of two cases. *BMC Gastroenterol* 2006; **6**: 25
  - 46 **Maehara N**, Chijiwa K, Makino I, Ohuchida J, Kai M, Kondo K, Moriguchi S, Marutsuka K, Asada Y. Segmentectomy for reactive lymphoid hyperplasia of the liver: Report of a case. *Surg Today* 2006; **36**: 1019-1023
  - 47 **Willenbrock K**, Kriener S, Oeschger S, Hansmann ML. Nodular lymphoid lesion of the liver with simultaneous focal nodular hyperplasia and hemangioma: discrimination from primary hepatic MALT-type non-Hodgkin's lymphoma. *Virchows Arch* 2006; **448**: 223-227
  - 48 **Machida T**, Takahashi T, Itoh T, Hirayama M, Morita T, Horita S. Reactive lymphoid hyperplasia of the liver: a case report and review of literature. *World J Gastroenterol* 2007; **13**: 5403-5407
  - 49 **Matsumoto N**, Ogawa M, Kawabata M, Tohne R, Hiroi Y, Furuta T, Yamamoto T, Gotoh I, Ishiwata H, Ono Y, Arakawa Y, Kinukawa N. Pseudolymphoma of the liver: Sonographic findings and review of the literature. *J Clin Ultrasound* 2007; **35**: 284-288
  - 50 **Jiménez R**, Beguiristain A, Ruiz-Montesinos I, Villar F, Medrano MA, Garnateo F, Vaquero J, Elizondo ME. Nodular lymphoid hyperplasia of the liver. Pseudolymphoma. *Rev Esp Enferm Dig* 2007; **99**: 299-306
  - 51 **Park HS**, Jang KY, Kim YK, Cho BH, Moon WS. Histiocytic reactive lymphoid hyperplasia of the liver: unusual morphologic features. *J Korean Med Sci* 2008; **23**: 156-160

S- Editor Li LF L- Editor Cant MR E- Editor Ma WH